LiRIS® 400 mg ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
226	間質性膀胱炎（ハンナ型）	3

226. 間質性膀胱炎（ハンナ型）

---

臨床試験数 : 145 /  薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02395042 (ClinicalTrials.gov)	April 15, 2015	17/3/2015	A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions	A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions	Cystitis, Interstitial;Ulcer	Drug: LiRIS®;Drug: LiRIS Placebo	Allergan	NULL	Completed	18 Years	N/A	Female	59	Phase 2	United States;Canada
2	NCT01879683 (ClinicalTrials.gov)	July 2013	10/6/2013	A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions	A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial Cystitis	Chronic Interstitial Cystitis	Drug: LiRIS® 400 mg	Allergan	TARIS Biomedical, Inc.	Completed	18 Years	N/A	Female	10	Phase 1	United States
3	NCT01824303 (ClinicalTrials.gov)	March 2013	31/3/2013	Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis	A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension	Interstitial Cystitis	Drug: LiRIS 400 mg;Other: LiRIS Placebo	Allergan	TARIS Biomedical, Inc.	Terminated	18 Years	N/A	Female	31	Phase 2	United States;Canada